These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29265939)

  • 21. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
    Hrarat L; Fajnkuchen F; Boubaya M; Lévy V; Sarda V; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    Ophthalmologica; 2016; 236(4):207-214. PubMed ID: 27898414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
    Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
    Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
    Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
    Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of selective retina therapy for diabetic macular edema based on pretreatment central foveal thickness.
    Kim M; Park YG; Jeon SH; Choi SY; Roh YJ
    Lasers Med Sci; 2020 Oct; 35(8):1781-1790. PubMed ID: 32095921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity.
    Sacconi R; Battaglia Parodi M; Casati S; Lattanzio R; Marchini G; Bandello F
    Ophthalmic Res; 2017; 58(3):125-130. PubMed ID: 28704825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
    Kim M; Lee P; Kim Y; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of postvitrectomy intravitreal triamcinolone therapy for diabetic macular edema.
    Costa JF; Sousa K; Marques JP; Marques M; Cachulo ML; Silva R; Gomes N; Figueira J
    Eur J Ophthalmol; 2016 Aug; 26(5):485-90. PubMed ID: 26951531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.
    Rosenblatt A; Udaondo P; Cunha-Vaz J; Sivaprasad S; Bandello F; Lanzetta P; Kodjikian L; Goldstein M; Habot-Wilner Z; Loewenstein A;
    Ophthalmology; 2020 Mar; 127(3):377-393. PubMed ID: 31932090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study.
    Brasil OF; Smith SD; Galor A; Lowder CY; Sears JE; Kaiser PK
    Br J Ophthalmol; 2007 Jun; 91(6):761-5. PubMed ID: 17108013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.